268 related articles for article (PubMed ID: 37236196)
1. CDKN2A deletion remodels lipid metabolism to prime glioblastoma for ferroptosis.
Minami JK; Morrow D; Bayley NA; Fernandez EG; Salinas JJ; Tse C; Zhu H; Su B; Plawat R; Jones A; Sammarco A; Liau LM; Graeber TG; Williams KJ; Cloughesy TF; Dixon SJ; Bensinger SJ; Nathanson DA
Cancer Cell; 2023 Jun; 41(6):1048-1060.e9. PubMed ID: 37236196
[TBL] [Abstract][Full Text] [Related]
2. The Tumor Suppressor CDKN2A Remodels the Lipidome of Glioblastoma.
Cancer Discov; 2023 Aug; 13(8):1760. PubMed ID: 37294124
[TBL] [Abstract][Full Text] [Related]
3. Altered lipid metabolism marks glioblastoma stem and non-stem cells in separate tumor niches.
Shakya S; Gromovsky AD; Hale JS; Knudsen AM; Prager B; Wallace LC; Penalva LOF; Brown HA; Kristensen BW; Rich JN; Lathia JD; Brown JM; Hubert CG
Acta Neuropathol Commun; 2021 May; 9(1):101. PubMed ID: 34059134
[TBL] [Abstract][Full Text] [Related]
4. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.
Cen L; Carlson BL; Schroeder MA; Ostrem JL; Kitange GJ; Mladek AC; Fink SR; Decker PA; Wu W; Kim JS; Waldman T; Jenkins RB; Sarkaria JN
Neuro Oncol; 2012 Jul; 14(7):870-81. PubMed ID: 22711607
[TBL] [Abstract][Full Text] [Related]
5. CircRNF10 triggers a positive feedback loop to facilitate progression of glioblastoma via redeploying the ferroptosis defense in GSCs.
Wang C; Zhang M; Liu Y; Cui D; Gao L; Jiang Y
J Exp Clin Cancer Res; 2023 Sep; 42(1):242. PubMed ID: 37723588
[TBL] [Abstract][Full Text] [Related]
6. BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity.
Nakajima N; Nobusawa S; Nakata S; Nakada M; Yamazaki T; Matsumura N; Harada K; Matsuda H; Funata N; Nagai S; Nakamura H; Sasaki A; Akimoto J; Hirato J; Yokoo H
Brain Pathol; 2018 Sep; 28(5):663-673. PubMed ID: 29105198
[TBL] [Abstract][Full Text] [Related]
7. FISH analysis reveals CDKN2A and IFNA14 co-deletion is heterogeneous and is a prominent feature of glioblastoma.
Al Shboul S; Boyle S; Singh A; Saleh T; Alrjoub M; Abu Al Karsaneh O; Mryyian A; Dawoud R; Gul S; Abu Baker S; Ball K; Hupp T; Brennan PM
Brain Tumor Pathol; 2024 Jan; 41(1):4-17. PubMed ID: 38097874
[TBL] [Abstract][Full Text] [Related]
8. The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature.
Lu VM; O'Connor KP; Shah AH; Eichberg DG; Luther EM; Komotar RJ; Ivan ME
J Neurooncol; 2020 Jun; 148(2):221-229. PubMed ID: 32385699
[TBL] [Abstract][Full Text] [Related]
9. CDKN2A deletion in pediatric versus adult glioblastomas and predictive value of p16 immunohistochemistry.
Purkait S; Jha P; Sharma MC; Suri V; Sharma M; Kale SS; Sarkar C
Neuropathology; 2013 Aug; 33(4):405-12. PubMed ID: 23311918
[TBL] [Abstract][Full Text] [Related]
10. [Methylthioadenosine phosphorylase and p16 as surrogate diagnostic markers for CDKN2A homozygous deletion in brain tumors].
Wang SN; Wang W; Zhang XW; Zhang YQ; Xiong YL; Liu L; Teng LH
Zhonghua Bing Li Xue Za Zhi; 2024 May; 53(5):439-445. PubMed ID: 38678323
[No Abstract] [Full Text] [Related]
11. Genomic landscape of gliosarcoma: distinguishing features and targetable alterations.
Zaki MM; Mashouf LA; Woodward E; Langat P; Gupta S; Dunn IF; Wen PY; Nahed BV; Bi WL
Sci Rep; 2021 Sep; 11(1):18009. PubMed ID: 34504233
[TBL] [Abstract][Full Text] [Related]
12. Molecular genetics of radiographically defined de novo glioblastoma multiforme.
Tortosa A; Ino Y; Odell N; Swilley S; Sasaki H; Louis DN; Henson JW
Neuropathol Appl Neurobiol; 2000 Dec; 26(6):544-52. PubMed ID: 11123721
[TBL] [Abstract][Full Text] [Related]
13. A recombinant lentiviral PDGF-driven mouse model of proneural glioblastoma.
Rahme GJ; Luikart BW; Cheng C; Israel MA
Neuro Oncol; 2018 Feb; 20(3):332-342. PubMed ID: 29016807
[TBL] [Abstract][Full Text] [Related]
14. A new method of identifying glioblastoma subtypes and creation of corresponding animal models.
Zhou X; Li G; An S; Li WX; Yang H; Guo Y; Dai Z; Dai S; Zheng J; Huang J; Iavarone A; Zhao X
Oncogene; 2018 Aug; 37(35):4781-4791. PubMed ID: 29769617
[TBL] [Abstract][Full Text] [Related]
15. Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups.
Hinrichs BH; Newman S; Appin CL; Dunn W; Cooper L; Pauly R; Kowalski J; Rossi MR; Brat DJ
Acta Neuropathol Commun; 2016 Jan; 4():4. PubMed ID: 26757882
[TBL] [Abstract][Full Text] [Related]
16. The CDKN2A G500 allele is more frequent in GBM patients with no defined telomere maintenance mechanism tumors and is associated with poorer survival.
Royds JA; Al Nadaf S; Wiles AK; Chen YJ; Ahn A; Shaw A; Bowie S; Lam F; Baguley BC; Braithwaite AW; MacFarlane MR; Hung NA; Slatter TL
PLoS One; 2011; 6(10):e26737. PubMed ID: 22046342
[TBL] [Abstract][Full Text] [Related]
17. Application of novel PACS-based informatics platform to identify imaging based predictors of CDKN2A allelic status in glioblastomas.
Tillmanns N; Lost J; Tabor J; Vasandani S; Vetsa S; Marianayagam N; Yalcin K; Erson-Omay EZ; von Reppert M; Jekel L; Merkaj S; Ramakrishnan D; Avesta A; de Oliveira Santo ID; Jin L; Huttner A; Bousabarah K; Ikuta I; Lin M; Aneja S; Turowski B; Aboian M; Moliterno J
Sci Rep; 2023 Dec; 13(1):22942. PubMed ID: 38135704
[TBL] [Abstract][Full Text] [Related]
18. Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.
Acquaviva J; Jun HJ; Lessard J; Ruiz R; Zhu H; Donovan M; Woolfenden S; Boskovitz A; Raval A; Bronson RT; Pfannl R; Whittaker CA; Housman DE; Charest A
Cancer Res; 2011 Dec; 71(23):7198-206. PubMed ID: 21987724
[TBL] [Abstract][Full Text] [Related]
19. CDK4, CDK6, cyclin D1, p16(INK4a) and EGFR expression in glioblastoma with a primitive neuronal component.
Xu G; Li JY
J Neurooncol; 2018 Feb; 136(3):445-452. PubMed ID: 29150788
[TBL] [Abstract][Full Text] [Related]
20. NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation.
Su IC; Su YK; Setiawan SA; Yadav VK; Fong IH; Yeh CT; Lin CM; Liu HW
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
